Protagonist Therapeutics, Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $40.93 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-25
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.17, a 57.82% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $28.85, a 23.24% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $23.41, a 200.90% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $7.78, a 2.38% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $40.93, a 67.81% increase from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $24.39, a 86.61% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.07, a 41.63% decline from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $22.39, a 25.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $40.93 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $24.39 10-K · filed 2025-02-21 | |||
| 2023-12-31 | $13.07 10-K · filed 2024-02-27 | |||
| 2023-06-30 | $12.61 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $12.17 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $22.39 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $23.87 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $25.47 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $28.85 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $29.96 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $29.93 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $26.97 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $23.41 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $11.53 10-K · filed 2021-03-10 | |||
| 2020-09-30 | $10.32 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $8.51 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $7.78 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $9.36 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $9.32 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $8.75 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $7.97 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $13.51 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $14.70 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $16.91 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |